CATTALINI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 6.771
EU - Europa 4.304
AS - Asia 3.808
SA - Sud America 864
Continente sconosciuto - Info sul continente non disponibili 280
AF - Africa 92
OC - Oceania 20
Totale 16.139
Nazione #
US - Stati Uniti d'America 6.615
PL - Polonia 1.610
SG - Singapore 1.347
CN - Cina 993
BR - Brasile 712
IT - Italia 538
HK - Hong Kong 503
FR - Francia 471
UA - Ucraina 470
DE - Germania 383
VN - Vietnam 352
FI - Finlandia 233
GB - Regno Unito 173
RU - Federazione Russa 144
BD - Bangladesh 142
TR - Turchia 139
IE - Irlanda 106
IN - India 91
CA - Canada 73
ID - Indonesia 62
AR - Argentina 53
MX - Messico 38
NL - Olanda 32
EC - Ecuador 30
IQ - Iraq 27
SE - Svezia 25
ZA - Sudafrica 25
ES - Italia 24
BE - Belgio 23
CO - Colombia 23
JP - Giappone 22
AT - Austria 19
AU - Australia 19
PK - Pakistan 18
SA - Arabia Saudita 16
MA - Marocco 14
EG - Egitto 12
VE - Venezuela 11
CZ - Repubblica Ceca 10
PH - Filippine 10
HN - Honduras 9
PE - Perù 9
PY - Paraguay 9
UZ - Uzbekistan 9
DZ - Algeria 8
JM - Giamaica 8
KG - Kirghizistan 8
NG - Nigeria 8
AZ - Azerbaigian 7
CR - Costa Rica 7
KE - Kenya 7
UY - Uruguay 7
CH - Svizzera 6
IL - Israele 6
IR - Iran 6
MY - Malesia 6
TN - Tunisia 6
CL - Cile 5
DK - Danimarca 5
EU - Europa 5
JO - Giordania 5
LT - Lituania 5
NP - Nepal 5
SN - Senegal 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
HU - Ungheria 4
NI - Nicaragua 4
AL - Albania 3
AM - Armenia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GT - Guatemala 3
KZ - Kazakistan 3
LB - Libano 3
PS - Palestinian Territory 3
QA - Qatar 3
RO - Romania 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
EE - Estonia 2
GR - Grecia 2
KH - Cambogia 2
PT - Portogallo 2
SC - Seychelles 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AW - Aruba 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
FK - Isole Falkland (Malvinas) 1
GI - Gibilterra 1
IM - Isola di Man 1
Totale 15.851
Città #
Warsaw 1.609
Singapore 666
Fairfield 628
Ashburn 612
Woodbridge 515
Hong Kong 501
Jacksonville 358
Houston 352
San Jose 292
The Dalles 275
Beijing 254
Seattle 244
Cambridge 225
Wilmington 218
Ann Arbor 206
Chandler 186
New York 182
Council Bluffs 169
Princeton 165
Helsinki 161
Los Angeles 143
Istanbul 116
Lauterbourg 113
Ho Chi Minh City 109
Dublin 106
Nanjing 88
Columbus 81
Munich 81
Dong Ket 70
Brescia 69
Milan 67
Des Moines 65
Santa Clara 65
São Paulo 64
Hanoi 55
Redondo Beach 54
Chicago 52
Dallas 49
Moscow 49
San Francisco 47
Buffalo 42
Shenyang 42
Jakarta 40
Shanghai 39
Nanchang 38
San Diego 37
Phoenix 31
Orem 30
Rome 29
Changsha 26
Dearborn 25
Lancaster 24
Chennai 23
Turku 23
Atlanta 22
Hebei 22
London 22
Nuremberg 22
Boardman 21
Rio de Janeiro 21
Tianjin 21
Brussels 20
Denver 20
Toronto 20
Frankfurt am Main 19
Jinan 19
Lappeenranta 18
Montreal 17
Tokyo 17
Romola 15
Assemini 14
Belo Horizonte 14
Johannesburg 14
Ningbo 14
Paris 14
Poplar 14
Guangzhou 13
Mexico City 13
Zhengzhou 13
Baghdad 12
Brooklyn 12
Charlotte 12
Naples 12
Salt Lake City 12
Brasília 11
Goiânia 11
Porto Alegre 11
Quito 11
Stockholm 11
Boston 10
Campinas 10
Dhaka 10
Haiphong 10
Turin 10
Amsterdam 9
Da Nang 9
Düsseldorf 9
Hyderabad 9
Salvador 9
Trieste 9
Totale 10.468
Nome #
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study 341
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry 340
Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease 330
A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry 311
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 307
Developing a Predictive Score for Chronic Arthritis among a Cohort of Children with Musculoskeletal Complaints - The Chronic Arthritis Score Study 293
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 269
Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: A case series 254
Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders 253
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis 248
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 243
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 239
When flexibility is not necessarily a virtue: a review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children 235
Canakinumab for the treatment of autoinflammatory recurrent fever syndromes 218
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 208
Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. 201
Clinical and Laboratory Features of 184 Italian Pediatric Patients Affected with Selective IgA Deficiency (SIgAD): a Longitudinal Single-Center Study 191
IPSC-DERIVED NEURONS AS AN IN VITRO MODEL FOR THE STUDY OF INTERFERONOPATHIES WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT 188
Allele *1 of HS1.2 enhancer associates with selective IgA deficiency and IgM concentration. 180
Autosomal recessive agammaglobulinemia: novel insights from mutations in Ig-beta 178
Body experiences, emotional competence, and psychosocial functioning in juvenile idiopathic arthritis. 178
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 175
DISCRIMINATION AMONG MONOGENIC AND ACQUIRED DISEASE WITH INFLAMMATORY AND AUTOIMMUNE COMPONENT THROUGH THE IN VITRO STUDY OF SIGNAL TRANSDUCERS OF TYPE I INTERFERON 165
The change in Ig regulation from children to adults disconnects the correlation with the 3'RR hs1.2 polymorphism 165
In silico validation of the autoinflammatory disease damage index 160
Profound T-cell defects in Dubowitz syndrome 158
Aicardi Goutieres Syndrome: New Insights on a Novel Set of Inborn Errors of Immunity 157
Mycoplasma infection may complicate the clinical course of SARS-Co-V-2 associated Kawasaki-like disease in children 154
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry 149
Development of the autoinflammatory disease damage index (ADDI) 148
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome 147
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease 145
Establishment of three iPSC lines from fibroblasts of a patient with Aicardi Goutières syndrome mutated in RNaseH2B 144
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 142
Condylar asymmetry in patients with juvenile idiopathic arthritis: Could it be a sign of a possible temporomandibular joints involvement? 138
Chronic nonbacterial osteomyelitis may be associated with renal disease and bisphosphonates are a good option for the majority of patients 138
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: A series of 486 cases from the Eurofever international registry 138
Cooperative intervention to assist children with HIV-infection in Burkina Faso: The Brescia experience during the pilot phase of the ESTHER Project. 137
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 137
Generation of three isogenic induced Pluripotent Stem Cell lines (iPSCs) from fibroblasts of a patient with Aicardi Goutières Syndrome carrying a c.2471G>A dominant mutation in IFIH1 gene 136
Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome 132
Sex Differences in Pediatric Rheumatology 131
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra 130
Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis 130
Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. 127
Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. 126
Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra 126
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee 126
Differentiating PFAPA syndrome from monogenic periodic fevers. 124
Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists’ lens 122
Musculoskeletal pain in children, when hypermobility is the problem 122
Generation of three iPSC lines from fibroblasts of a patient with Aicardi Goutières Syndrome mutated in TREX1 120
Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. 118
Overview of fever of unknown origin in adult and paediatric patients 109
Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome 107
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases 106
Contraception in adolescents with systemic lupus erythematosus 105
Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient 105
INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry 104
Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. 101
Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis 101
Serum amyloid protein A concentration in cryopyrin-associated periodic syndromes patients treated with interleukin-1 beta antagonist 99
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 98
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis 96
Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ 96
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis 95
Longitudinal Characterization of Immune Response in a Cohort of Children Hospitalized with Multisystem Inflammatory Syndrome 95
Intervento di Cooperazione sanitaria per l'assistenza ai bambini affetti da HIV/AIDS in Burkina Faso: l'esperienza della Clinica Pediatrica di Brescia. 95
Pitfalls of flow cytometric analysis by dihidrorodamyne-123 in the diagnosis of chronic granulomatous disease. 95
Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-LabelComparative Study of Adalimumab Versus Infliximab 94
Favourable and sustained response to anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. 92
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network 91
Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation 91
Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome 90
A patient-driven registry on Behçet's disease: the AIDA for patients pilot project 89
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 89
Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome 88
Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets 88
Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry 86
Pitfalls of flow cytometric analysis by dihydrorodamine-123 in the diagnosis of chronic granulomatous disease 86
Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics 85
Predicting duration of beneficial effect of joint injection among children with chronic arthritis by measuring biomarkers concentration in synovial fluid at the time of injection. 85
Musculoskeletal manifestations in hereditary periodic fever syndromes 85
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network 85
The Spectrum of Manifestations of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) Infection in Children: What We Can Learn From Multisystem Inflammatory Syndrome in Children (MIS-C) 84
iPSC-derived 3d brain organoids cultured in a bioreactor as an in vitro model for the study of microcephaly in Aicardi Goutières syndrome. 83
Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity 83
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor - Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network 83
Inflammatory pathways signal transducers analysis in iPSC-derived neurons and 3D cerebral organoids 82
OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis 81
Prevalence of cranial involvement in a cohort of Italian patients with chronic non-bacterial osteomyelitis 81
Covid-19 and autoimmunity 81
Treatment response to Janus kinase inhibitor in a child affected by Aicardi-Goutières syndrome 80
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 78
Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry 76
Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry 76
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease 76
The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C 76
iPSC-derived 3d brain organoids cultured in a bioreactor as an in vitro model for the study of microcephaly in Aicardi Goutières syndrome 75
Cardiac MRI in midterm follow-up of MISC: a multicenter study 74
Totale 13.872
Categoria #
all - tutte 78.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.723


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022559 0 0 28 55 6 39 29 59 35 86 56 166
2022/2023609 91 6 8 59 50 175 11 53 91 7 29 29
2023/2024867 53 20 92 65 25 150 30 37 250 8 17 120
2024/20252.325 11 28 31 358 241 161 214 106 298 186 385 306
2025/20264.830 416 589 377 730 402 306 634 163 296 426 288 203
2026/2027663 234 261 168 0 0 0 0 0 0 0 0 0
Totale 16.139